GlaxoSmithKline, the UK-based pharmaceutical company headed by Jean-Pierre Garnier, has received a fresh blow to the prospects for Avandia, its diabetes drug, with European regulators imposing tighter restrictions on its use.
The European Medicines Agency (EMEA) warned that the drug, among the most important in GSK's portfolio, should only be prescribed after careful evaluation to patients suffering from ischaemic heart disease, or reduced blood supply to the heart muscle. It added that it should only be used in combination with insulin "in exceptional cases and under close supervision".
More at the FT
Insider's view: the Avandia users club will soon be holding their annual general meeting in a phone box near you!
Hat tip: Jimmie
Post a Comment